 |
NORWALK, Conn., Oct. 8, 2025 /PRNewswire/ — LBB Specialties (LBBS), a North American distributor of specialty chemicals and ingredients providing technical solutions with a customer-first approach, today announced an expansion of its partnership with Givaudan Active Beauty to include a broader range of Care ingredients in the Midwest and East United States.
This agreement builds on LBBS’s existing distribution of Givaudan’s Neossance® squalane and hemisqualane, extending the collaboration in these regions to additional active ingredients, premium specialties, and biotech solutions for Skin, Hair, Make Up or Body formulas and launches.
Through this partnership, LBBS will collaborate with Givaudan to strengthen customer support in the Midwest and East, combining efforts to serve existing customers and reach new ones with Givaudan’s world-class technologies.
“As a customer-focused company, we’re always striving to expand our product offerings to support the innovation needs of our partners and customers,” said Thomas Van Valkenburgh, President & CEO of LBB Specialties. “This expansion with Givaudan is another important step forward, allowing us to bring more of their renowned technologies to formulators and brands in the Midwest and East.”
For more information about Givaudan Active Beauty’s cosmetic ingredient solutions, please contact LBB Specialties today.
About LBB Specialties
LBB Specialties is a dedicated provider of specialty chemicals and ingredients, specializing in sales, marketing, and distribution across North America. We provide technical solutions with a customer-first approach, serving diverse end-markets through five industry and market business units: Care, Food & Nutrition, Industrial Specialties, Life Sciences, and Canada. www.LBBSpecialties.com
Media Contact:
Ahmed Hanafy
[email protected]
ข่าวที่เกี่ยวข้อง
- New Era for School STEM: Cosmofluencer Launches CosmoClub with Fizzics Education’s India Entry
- ผลการศึกษาระยะ 3 ปีของ SIRONA: บอลลูนเคลือบยาไซโรลิมัสแสดงผลดีกว่าบอลลูนเคลือบยาแพคลิแทกเซล ในด้านการลดโอกาสที่ผู้ป่วยโรคหลอดเลือดแดงบริเวณต้นขาและข้อพับเข่าจะต้องเข้ารับการเปิดหลอดเลือดซ้ำ
- Transportation Q&A for the 9th CIIE
- Minghui Pharmaceutical and ASKA Pharmaceutical Enter into Exclusive License Agreement for the IGF-1R Antibody in Japan
